This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
相关报告
宏观经济五十图:2023年一季度-20230208-34页
625
类型:宏观
上传时间:2023-02
标签:宏观经济、2023Q1、五十图)
语言:中文
金额:免费
PitchBook-2023年一季度全球房地产报告(英)-2023
357
类型:行研
上传时间:2023-06
标签:房地产、置业、2023Q1)
语言:英文
金额:5积分
硅谷银行-2023年第一季度经济报告(英)-2023.2
336
类型:宏观
上传时间:2023-03
标签:2023Q1、经济报告)
语言:英文
金额:5积分
2023年第一季度机器人投资报告(英)
225
类型:行研
上传时间:2023-05
标签:2023Q1、机器人、科技)
语言:英文
金额:5积分
赛诺菲 2023年第一季度报告 slides-1684136192
218
类型:公司/个股
上传时间:2023-05
标签:2023Q1、财报、赛诺菲)
语言:英文
金额:5积分
Crypto Fund Research-2023年第一季度加密基金报告(英)
216
类型:行研
上传时间:2023-07
标签:加密基金、2023Q1)
语言:英文
金额:5积分
特斯拉2023年Q1财报TSLA-Q1-2023-Update-3
181
类型:公司/个股
上传时间:2024-01
标签:2023Q1、特斯拉、财报)
语言:英文
金额:5积分
2023年第一季度太空投资报告(英)
172
类型:行研
上传时间:2023-05
标签:太空、2023Q1)
语言:英文
金额:5积分
SEG-2023年第一季度SaaS并购更新(英)-2023.4
167
类型:专题
上传时间:2023-04
标签:SaaS、并购、2023Q1)
语言:英文
金额:5积分
2023年第一季度播客指标报告(英)
147
类型:专题
上传时间:2023-03
标签:2023Q1、播客指标)
语言:英文
金额:5积分
积分充值
30积分
6.00元
90积分
18.00元
150+8积分
30.00元
340+20积分
68.00元
640+50积分
128.00元
990+70积分
198.00元
1640+140积分
328.00元
微信支付
余额支付
积分充值
应付金额:
0 元
请登录,再发表你的看法
登录/注册